Therefore, our results, clearly suggest the role of saroglitazar in the amelioration of hyperleptinemia and leptin resistance which may be one of the potential mechanisms for alleviation of obesity and has not been revealed earlier in the MSG model of obesity. Here, LEP is linked to obesity disorder.